SG11201806819UA - Cancer treatment combination compositions, methods and uses - Google Patents
Cancer treatment combination compositions, methods and usesInfo
- Publication number
- SG11201806819UA SG11201806819UA SG11201806819UA SG11201806819UA SG11201806819UA SG 11201806819U A SG11201806819U A SG 11201806819UA SG 11201806819U A SG11201806819U A SG 11201806819UA SG 11201806819U A SG11201806819U A SG 11201806819UA SG 11201806819U A SG11201806819U A SG 11201806819UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lhrh
- curcumin
- louisiana
- ana
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662294497P | 2016-02-12 | 2016-02-12 | |
PCT/US2017/017471 WO2017139644A1 (en) | 2016-02-12 | 2017-02-10 | Cancer treatment combination compositions, methods and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806819UA true SG11201806819UA (en) | 2018-09-27 |
Family
ID=59563550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806819UA SG11201806819UA (en) | 2016-02-12 | 2017-02-10 | Cancer treatment combination compositions, methods and uses |
Country Status (9)
Country | Link |
---|---|
US (1) | US10603335B2 (zh) |
EP (1) | EP3413906B1 (zh) |
JP (1) | JP2019507749A (zh) |
KR (1) | KR20180123027A (zh) |
CN (1) | CN109475595A (zh) |
AU (1) | AU2017217953A1 (zh) |
CA (1) | CA3014433A1 (zh) |
SG (1) | SG11201806819UA (zh) |
WO (1) | WO2017139644A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200268697A1 (en) * | 2019-02-21 | 2020-08-27 | Florida Atlantic University Board Of Trustees | Inhibitors of autophagy and dcar-1 as novel anthelmintic agents |
EP3982942A4 (en) * | 2019-06-17 | 2023-06-07 | Mayo Foundation for Medical Education and Research | DRUG DELIVERY METHODS AND COMPOSITIONS |
WO2021167074A1 (ja) * | 2020-02-21 | 2021-08-26 | 東ソー株式会社 | 光反応性基を含む化合物、重合体、位相差膜 |
CN112007042B (zh) * | 2020-09-10 | 2023-02-21 | 中国医学科学院医学生物学研究所 | 阿糖胞苷与原癌蛋白c-FOS抑制剂在制备治疗白血病的产品中的应用 |
CN113694085A (zh) * | 2021-08-26 | 2021-11-26 | 广西医科大学 | 蛞蝓提取物在制备癌症化疗方案的联用药物中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030066927A (ko) * | 2002-02-06 | 2003-08-14 | 구자영 | 쿠르쿠민과 5-프루오로유라실로 이루어진 항암제 및 이항암제의 용도 |
US7355081B2 (en) * | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
CA2483340A1 (en) * | 2002-04-24 | 2003-11-06 | Research Development Foundation | Synergistic effects of nuclear transcription factor nf-.kappa.b inhibitors and anti-neoplastic agents |
US20050227929A1 (en) | 2003-11-13 | 2005-10-13 | Masferrer Jaime L | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent |
DK2252627T3 (en) * | 2008-01-24 | 2017-08-14 | Esperance Pharmaceuticals | MERGER CONSTRUCTION WITH LYTIC DOMAIN AND METHOD FOR PRODUCING AND USING SAME. |
US9221877B2 (en) * | 2008-09-19 | 2015-12-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Curcumin conjugates for treating and preventing cancers |
CN102670573A (zh) * | 2011-11-21 | 2012-09-19 | 西安交通大学 | 姜黄素衍生物在制备治疗前列腺癌疾病药物中的应用 |
CN102659950B (zh) * | 2012-04-19 | 2013-09-04 | 中国科学院长春应用化学研究所 | 键合了lhrh的两亲性可生物降解聚合物、制备方法和用途 |
-
2017
- 2017-02-10 US US15/430,123 patent/US10603335B2/en active Active
- 2017-02-10 AU AU2017217953A patent/AU2017217953A1/en not_active Abandoned
- 2017-02-10 EP EP17750872.8A patent/EP3413906B1/en active Active
- 2017-02-10 JP JP2018542707A patent/JP2019507749A/ja active Pending
- 2017-02-10 CA CA3014433A patent/CA3014433A1/en not_active Abandoned
- 2017-02-10 KR KR1020187025756A patent/KR20180123027A/ko unknown
- 2017-02-10 CN CN201780022742.6A patent/CN109475595A/zh active Pending
- 2017-02-10 SG SG11201806819UA patent/SG11201806819UA/en unknown
- 2017-02-10 WO PCT/US2017/017471 patent/WO2017139644A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN109475595A (zh) | 2019-03-15 |
EP3413906A4 (en) | 2019-10-16 |
AU2017217953A1 (en) | 2018-09-13 |
US10603335B2 (en) | 2020-03-31 |
KR20180123027A (ko) | 2018-11-14 |
JP2019507749A (ja) | 2019-03-22 |
CA3014433A1 (en) | 2017-08-17 |
US20170258929A1 (en) | 2017-09-14 |
EP3413906B1 (en) | 2021-10-27 |
EP3413906A1 (en) | 2018-12-19 |
WO2017139644A1 (en) | 2017-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806819UA (en) | Cancer treatment combination compositions, methods and uses | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201906223TA (en) | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
SG11201900501RA (en) | Cannabis composition | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201900975XA (en) | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11201901501UA (en) | Compositions and methods for enhancing cancer radiotherapy | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
SG11201900228YA (en) | Administration and dosage of diaminophenothiazines | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201803834UA (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
SG11201903431SA (en) | Sstr-targeted conjugates and particles and formulations thereof | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201906543RA (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
SG11201900361RA (en) | Methods of treating prostate cancer | |
SG11201909840TA (en) | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |